Drug Combination Details
| General Information of the Combination (ID: C26930) | |||||
|---|---|---|---|---|---|
| Name | Bucillamine | + | Salazosulfapyridine + Methotrexate | ||
| Click to Show/Hide the Each NP or Drug Information of This Combination | |||||
| Name | Bucillamine NP Info | Drug Info | |||
| Structure |
|
|
|||
| Name | Drug Info | ||||
| Structure |
|
|
|||
| Disease |
Rheumatoid arthritis
[ICD-11: FA20]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vivo Model | Clinical Trial | |||||
| Experimental
Result(s) |
The triple DMARD combination therapy provided a new treatment option for those patients for whom treatment with biologics is difficult. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis. Mod Rheumatol. 2016;26(1):51-6. | |||
